Clinical Trials Browser

Phase 3 × Pathologic Complete Response × sargramostim × Clear all

NCT04229979 2025-10-01

REGAL

Phase 3 Active not recruiting

Other hematologic neoplasm

Pathologic Complete Response, Leukemia, Myeloid, Acute